{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-020731","form_type":"8-K","ticker":"DYAI","cik":"0001213809","company_name":"DYADIC INTERNATIONAL INC","filed_at":"2025-07-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.514198+00:00","generated_at":"2026-05-18T03:13:53.007477+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"low","headline":"Dyadic posts strategic presentation; no specific financial or operational updates","bullets":["Presentation posted July 23, 2025 highlights transition from research to commercial focus.","Focus on C1 and Dapibus gene expression platforms for non-therapeutic protein production.","No specific financial targets, revenue guidance, or operational metrics disclosed.","Presentation will be used at industry and investor conferences."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-020731","json":"https://secwatch.observer/filing/0001641172-25-020731.json","markdown":"https://secwatch.observer/filing/0001641172-25-020731.md","text":"https://secwatch.observer/filing/0001641172-25-020731.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213809/000164117225020731/0001641172-25-020731-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213809/000164117225020731/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T03:13:53.007477+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}